An experimental drug designed with the help of artificial intelligence has produced early evidence that it may do more than treat idiopathic pulmonary fibrosis: it may influence biological aging itself. Rentosertib, developed by using AI to identify the TNIK protein as a target and generative AI to design a molecule capable of inhibiting it, was evaluated through blood samples collected during a randomized Phase 2a clinical trial. Researchers analyzed 2,841 proteins from 42 participants using six independently developed proteomic “aging clocks,” and all six registered movement toward younger predicted biological ages among treated patients. The strongest signal appeared in patients receiving 30 milligrams twice daily, with several models estimating biological-age reductions of roughly three to four years and one reaching approximately six years. The findings are potentially important because different aging models pointed in the same direction, but they remain preliminary: the participants suffered from a serious age-associated lung disease, making it impossible to determine conclusively whether the apparent rejuvenation reflects a genuine slowing of aging or simply biological improvement resulting from treatment of pulmonary fibrosis. Rentosertib has nevertheless advanced into Phase 3 testing for pulmonary fibrosis, making it an important test of whether AI can accelerate drug discovery while potentially identifying therapies that address both specific diseases and the underlying biology associated with aging.
Key Takeaways
- Rentosertib produced reductions in predicted biological age across all six independently developed proteomic aging clocks, with the strongest results appearing in the 30-milligram twice-daily group and some estimates suggesting three to six years of biological-age reversal.
- The results do not yet establish that rentosertib reverses human aging. The study involved only 42 analyzed patients suffering from idiopathic pulmonary fibrosis, and researchers cannot completely distinguish genuine geroprotective effects from improvements associated with treating the underlying lung disease.
- The larger development may be the emergence of AI as a serious drug-discovery platform: artificial intelligence helped identify TNIK as the biological target, helped design rentosertib, and may now provide a model for developing drugs that simultaneously attack specific diseases and mechanisms associated with aging.
In-Depth
Rentosertib, an experimental drug created with artificial intelligence to treat idiopathic pulmonary fibrosis, has produced an intriguing secondary finding: patients receiving the drug showed declines in predicted biological age across six independently developed proteomic aging clocks. The result offers an example of AI moving beyond administrative efficiencies and into the discovery of molecules that may affect fundamental biological processes.
The analysis drew on serum samples from 42 participants in a randomized Phase 2a lung-disease trial. Researchers measured 2,841 proteins and applied six aging models. All six detected movement toward younger biological-age profiles in treated patients, while placebo recipients generally showed little change or slight increases. The strongest and most consistent signal appeared with 30 milligrams twice daily, around week four. Some estimates suggested biological-age reductions of roughly three to four years, with one clock indicating as much as six.
That finding deserves attention, but not hype. The participants had pulmonary fibrosis, not normal aging, and improving a disease can itself alter biomarkers associated with age. Researchers acknowledge that the study cannot separate an anti-aging effect from the drug’s anti-fibrotic action. Healthy-volunteer trials will be needed.
Still, the broader significance is substantial. AI helped identify TNIK as a therapeutic target and helped design the molecule aimed at it. Rentosertib has since advanced into Phase 3 testing for pulmonary fibrosis. If studies confirm an independent geroprotective effect, the achievement would demonstrate something larger than one drug: AI could become a powerful engine for finding therapies that target aging biology while treating disease.